BiotechTube
OncoResponse

OncoResponse

Seattle, United States· Est.
oncoresponse.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $127M

Overview

OncoResponse is a Seattle-based, privately-held biotech founded in 2015, focused on immuno-oncology. The company's core strategy involves mining the B-cell repertoires of Elite Cancer Responders—patients with exceptional, durable responses to immunotherapy—to discover fully human monoclonal antibodies against novel immunosuppressive targets, particularly in the myeloid cell compartment. Its preclinical pipeline aims to overcome resistance in the tumor microenvironment (TME) and expand the benefits of immunotherapy to more patients. OncoResponse advances its programs through internal R&D and strategic collaborations with pharmaceutical partners.

Oncology

Technology Platform

Proprietary platform that interrogates the B-cell repertoires of 'Elite Cancer Responders' (patients with exceptional responses to immunotherapy) to discover and develop fully human monoclonal antibodies against novel immunosuppressive targets in the tumor microenvironment, with a focus on myeloid biology.

Funding History

2
Total raised:$127M
Series B$80M
Series A$47M

Opportunities

The significant unmet need in immuno-oncology, where most patients do not respond to checkpoint inhibitors, creates a large market for combination therapies.
The company's myeloid-focused approach targets a key mechanism of resistance in 'cold' tumors, positioning it in a high-priority area of drug development.
Successful validation of its platform could yield a pipeline of multiple first-in-class antibody assets.

Risk Factors

High scientific risk that antibodies from rare responders will be effective as drugs in a broader population.
Intense competition in the myeloid-targeting space from larger, better-funded entities.
Financial risk associated with being a pre-revenue, private company dependent on raising capital to advance expensive preclinical and clinical programs.

Competitive Landscape

OncoResponse competes in the crowded and rapidly evolving field of next-generation immuno-oncology, specifically targeting myeloid cells in the TME. Competitors range from large pharma (e.g., Roche, Merck, BMS) to numerous biotechs (e.g., Jounce Therapeutics, Surface Oncology, Nurix Therapeutics) pursuing various modalities (antibodies, small molecules, cell therapies) against targets like CD47, SIRPα, CCR2, CSF1R, and CD73. Differentiation relies on the novelty of targets discovered via its elite responder platform.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →